Mouse anti Human Cytochrome P450 2A6Catalog number: X2045M
|Clone||F16 P2 D8|
Immunohistochemistry (frozen & paraffin)
The cytochrome P450 proteins (CYPs) are monooxygenases that catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. P450 enzymes are classified into subfamilies based on their sequence similarities. CYP2A6 is a liver enzyme that metabolizes a number of drugs and a variety of procarcinogens, though it is primarily responsible for the metabolism of nicotine, the major addictive agent in tobacco. CYP2A6 inactivates nicotine to cotinine, and then cotinine to 3-hydroxycotinine. Differences in CYP2A6 genotypes are related to nicotine dependence, and may influence smoking habits and withdrawal symptoms in individuals that are quitting smoking. This suggests that an individualized smoking cessation program may be designed based on CYP2A6 genotypes.
Synonyms: CYP2A6; CYP450 2A6 (EC 184.108.40.206), CYPIIA6, Coumarin 7-hydroxylase
Hybridoma produced by the fusion of splenocytes from BALB/c mice immunized with Synthetic peptide conjugated to ovalbumin derived from the C-terminus of CYP2A6 and mouse myeloma Ag8563 cells. Antigen identical in CYP2A6, 2A7 and 2A13.
Provided as solution in phosphate buffered saline with 0.08% sodium azide
Product Form: Unconjugated
Purification Method: Protein A/G Chromatography
Concentration: See vial for concentration
Antibody can be used for Western blotting (1-2 µg/ml), immunofluorescence and immunohistochemistry (formalin-fixed, paraffin-embedded tissues). ELISA titer to be determined by end-user. Optimal concentration should be evaluated by serial dilutions.
Functional Analysis: Western Blotting
Positive Control: Normal human liver tissue.
Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles
Product Stability: See expiration date on vial
Shipping Conditions: Ship at ambient temperature, freeze upon arrival
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Exalpha Biologicals accepts no liability for any inaccuracies or omissions in this information.
1. Kumarakulasingham M, et al. (2005). Cytochrome p450 profile of colorectal cancer: identification of markers of prognosis. Clin Cancer Res. May 15;11(10):3758-65 2. Swan, G.E. (2005). Nicotine metabolism: the impact of CYP2A6 on estimate of additive genetic influence. Pharmacogenet. Genomics 15(2);115-125 3. Higashi, E., et al. (2007). Inhibitory effects of neurotransmitters and steroids on human CYP2A6. Drug Metab Dispos. 35(4); 508-514 4. Audrain-McGovern, J., et al. (2007). The role of CYP2A6 in the emergence of nicotine dependence in adolescents. 119(1);264-274
Database Name: UniProt
Accession Number: P05177
Species Accession: Human
Safety Datasheet(s) for this product:
|"Left: Western blot using CYP2A6 antibody (Cat. No. X2045M) on recombinant cytochrome p450 at 1 µg/ml. Right: Staining using CYP2A6 antibody on normal human liver tissue at 1 µg/ml."|
"Left: Western blot using CYP2A6 antibody (Cat. No. X2045M) on recombinant cytochrome p450 at 1 µg/ml. Right: Staining using CYP2A6 antibody on normal human liver tissue at 1 µg/ml."